Insider Transactions in Q4 2025 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-4.19%
|
$160,000
$4.16 P/Share
|
|
Nov 19
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
40,000
+4.02%
|
-
|
|
Nov 17
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
40,390
-4.23%
|
$161,560
$4.14 P/Share
|
|
Nov 17
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,584
-2.33%
|
$70,336
$4.14 P/Share
|
|
Nov 17
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,908
-1.48%
|
$47,632
$4.14 P/Share
|
|
Nov 05
2025
|
Najat Khan Chief R&D Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,925
+10.13%
|
-
|
|
Nov 04
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Nov 04
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-3.94%
|
$200,000
$5.21 P/Share
|
|
Nov 04
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
60,000
+5.59%
|
-
|
|
Oct 23
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.49%
|
$500,000
$5.7 P/Share
|
|
Oct 23
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
100,000
+8.66%
|
-
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
20,000
-2.05%
|
-
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-9.31%
|
$600,000
$6.04 P/Share
|
|
Oct 10
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
120,000
+10.05%
|
-
|
|
Oct 01
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,941
+2.08%
|
-
|
|
Oct 01
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,961
+0.16%
|
-
|